Head and neck cancer metastatic
Not recruitingStudy of eftilagimod alpha with pembrolizumab combination therapy for patients with metastatic head and neck cancer who have not received previous treatment
Study of eftilagimod alpha with pembrolizumab combination therapy for patients with metastatic head and neck cancer who have not received previous treatment
- Disease:Head and neck cancer metastatic
- Substances:Eftilagimod AlfaPembrolizumab
Germany- Participants:18–64 years · 65+ years
- Substances:Eftilagimod Alfa
- Sponsor:Immutep









